At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 1,201 enrolled
Drug / intervention
Dihydroergotamine +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
EMERGE: A Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Single Doses of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine
In Brief
A Phase 3 clinical trial evaluating Dihydroergotamine and Placebos for Migraine and 2 related conditions. Completed, enrolled 1,201 participants across 117 sites.
Detailed Summary
Study STS101-002 is a randomized, double-blind, parallel group, placebo-controlled, multicenter study to evaluate the efficacy, safety, and tolerability of single doses of STS101 (dihydroergotamine nasal powder) in the acute treatment of migraine
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMigraine, Migraine With Aura, Migraine Without Aura
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
2020202120222023202420252026
First PostedApr 2019
Enrollment StartJun 2019
Primary CompletionJul 2020
Study CompletionAug 2020
TodayJul 2026
First PostedApr 3, 2019
Enrollment StartJun 24, 2019
Primary CompletionJul 31, 2020
Study CompletionAug 13, 2020
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 7.2 years ago
Interventions
Dihydroergotaminedrug
Dihydroergotamine is a semi-synthetic derivative of ergotamine tartrate.
Placebosdrug
Placebo for STS101